Skip to main content
. Author manuscript; available in PMC: 2019 May 27.
Published in final edited form as: J Hepatol. 2017 Feb 3;66(5):1037–1046. doi: 10.1016/j.jhep.2017.01.022

Fig. 4. MCC950 reverses NASH pathology.

Fig. 4.

(A) (i) Steatosis, (ii) hepatocyte ballooning, and (iii) NAFLD activity score (NAS) in Wt and foz/foz mice after 24 weeks atherogenic diet, and gavage during last 8 weeks with vehicle or MCC950. (B) Representative H&E-stained liver sections demonstrating inflammation in atherogenic foz/foz mouse liver (vehicle) is abolished by MCC950, with reduction of lobular inflammation score. (C) NF-κB activation (nuclear p65) is suppressed, as are, (D) myeloperoxidase (MPO) positive neutrophils, and (E) F4/80 positive macrophages and Kupffer cells as crown-like structures (CLS). Same experiments as Figs. 2 and 3. *p <0.05 vs. Wt. #p <0.05 MCC950 vs. vehicle, by one-way ANOVA, n = 11–13 animals/group. Scale bar: 100 μm.